San Diego Center for AIDS Research (SD CFAR)

University Of California, San Diego, La Jolla CA

Investigators

Linked publications & trials

Abstract

Enter the text here that is the new abstract information for your application. This section must be no longer than 30 lines of text. The mission of the San Diego Center for AIDS Research (SD CFAR) is to drive HIV discoveries and advance cutting-edge research by San Diego investigators to improve the lives of people with HIV and to stop new infections. Our Center’s research priorities are aligned with the NIH Office of AIDS Research priorities and include preventing new infections, optimizing HIV care, and developing a cure, while promoting health service reach for people with and at risk for HIV. The specific aims of the SD CFAR are to: 1. Accelerate the pace of discovery by providing the foundation for productive collaborations across fields, investigators, member institutions, and the HIV community. 2. Capitalize on our public engagement and partnerships to develop long-lasting research programs that can inform policy, practice, and implementation. 3. Provide Training, Inspiration, Mentoring, and Expert guidance (TIME) to local and collaborating investigators across career stages. 4. Provide scientific and administrative leadership to CFAR member institutions, investigators, and across our region. Structure: The SD CFAR is multi-institutional, with members at La Jolla Institute of Allergy and Immunology (LJI), San Diego State University (SDSU), Scripps Research (SR), and University of California San Diego (UCSD). The Center is co-directed by members of our Operations Team including Drs. Davey Smith (contact PI), Douglas Richman, Sonia Jain, Dennis Burton, and Jamila Stockman (Leadership Trainee). Our CFAR is comprised of seven Cores and one Scientific Working Group. We continue to be guided by our Advisory Committees, as well as our Co-Directors, Core Directors, Scientific Working Groups, and our membership. Progress: Since our renewal in 2017, SD CFAR efforts have yielded a productive and growing group of investigators whose research work extends from cellular restriction factors that impede HIV replication and transmission to behavioral approaches to improve prevention and treatment. Our funded research base remained at Tier 3 status and steadily increased by $11.9M between FY18 - 21. Further, there have been 870 CFAR-supported publications this past cycle, representing a 44.5% increase since the last renewal. We remain committed to supporting catalytic multidisciplinary research, bringing breakthroughs from laboratory bench to patient bedside, while fostering a new generation of innovative, independent investigators.